Dr. Tolaney on the APT and ATEMPT Trials in Stage I HER2+ Breast Cancer

Adjuvant treatment for stage I HER2+ breast cancerПодробнее

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancerПодробнее

Dr Tolaney on Ongoing Clinical Trials in Early-Stage HER2+ Breast CancerПодробнее

Dr. Tolaney on the ATEMPT Trial for HER2+ Breast CancerПодробнее

Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast CancerПодробнее

Dr. Tolaney on Deescalating Therapy in Stage I HER2+ Breast CancerПодробнее

ATEMPT Trial: Stage I HER2+ Breast CancerПодробнее

Sara Tolaney, SABCS 2022: Adjuvant paclitaxel and trastuzumab for node-negative HER2+ breast cancerПодробнее

Early-Stage HER2+ Breast Cancer: The ATEMPT TrialПодробнее

Dr. Burstein on the Results of the APT Trial for HER2+ Breast CancerПодробнее

Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast CancerПодробнее

Dr. Sara Tolaney on Adjuvant T-DM1 Vs Paclitaxel and Trastuzumab for Stage I HER2+ Breast CancerПодробнее

Dr. Tolaney on the Current Treatment Landscape for HER2+ Breast CancerПодробнее

Sara Tolaney MD, MPH shares results from the Phase 2 ATEMPT trial at SABCS 2019Подробнее

Dr. Tolaney on Activity With Abemaciclib in Patients With HR+/HER2– Breast CancerПодробнее

5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BCПодробнее

Dr. Tolaney on the Evolution of Adjuvant Treatment for HER2+ Breast CancerПодробнее

Dr Sara M. Tolaney: Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast CancerПодробнее

Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast CancerПодробнее